BrainChild Bio
Steven Brugger is the Chief Executive Officer of BrainChild Bio since December 2023. Prior to that, Steven held various leadership positions at companies such as Strategic Science and Technologies, LLC, GSK, Affinivax Inc., Visterra, Inc, Momenta Pharmaceuticals, Millennium Pharmaceuticals, Novartis Pharmaceuticals, and Ayerst Pharmaceuticals. Steven holds an MBA in Business from Rutgers University - Newark and a BA in Biology and Chemistry from Susquehanna University.
This person is not in any teams
This person is not in any offices
BrainChild Bio
We are a kids-first, clinical-stage biotechnology company focused on harnessing the power of CAR-T cell technology for tumors n the central nervous system (CNS), prioritizing pediatrics with plans to expand our technology to adult indications. We are building a platform to optimize the application of CAR-T technology in CNS tumors-- prioritizing diffuse intrinsic pontine glioma (DIPG) with plans to expand to other pediatric and adult brain tumors, including brain metastases.